When depression has not improved after multiple medications, the next decision can feel heavy. For many patients comparing TMS vs Spravato depression treatment, the real question is not which option sounds newer – it is which one fits your symptoms, medical history, daily life, and treatment goals.
Both TMS and Spravato are used for treatment-resistant depression, and both offer hope when standard approaches have fallen short. They are not interchangeable, though. They work differently in the brain, involve different treatment schedules, and come with different risks, benefits, and practical considerations. A careful evaluation helps determine which path makes the most sense for you.
TMS vs Spravato depression: the core difference
TMS, or transcranial magnetic stimulation, is a non-invasive treatment that uses targeted magnetic pulses to stimulate areas of the brain involved in mood regulation. It is FDA cleared for major depressive disorder in appropriate patients and does not require anesthesia or sedation. During treatment, you remain awake, alert, and able to return to your usual routine afterward.
Spravato is the brand name for esketamine, a prescription nasal spray used under medical supervision for adults with treatment-resistant depression and certain cases of major depressive disorder with acute suicidal thoughts or behaviors. Unlike a traditional antidepressant, Spravato acts on glutamate pathways and can work differently from medications that primarily target serotonin, norepinephrine, or dopamine.
That distinction matters. TMS is a device-based therapy that stimulates brain circuits over time. Spravato is a medication administered in a monitored clinical setting because it can cause temporary dissociation, sedation, and changes in blood pressure.
How TMS works for depression
TMS targets underactive regions of the brain associated with depression, most often the left dorsolateral prefrontal cortex. Repeated stimulation is designed to improve communication in brain networks linked to mood, motivation, and emotional regulation. The goal is not a short-lived shift in symptoms, but a more stable improvement that builds across a full course of treatment.
A typical TMS course involves treatments five days a week for several weeks, followed by tapering in some cases. Sessions are relatively brief, and many patients drive themselves to and from appointments. That convenience matters for adults balancing work, caregiving, or family responsibilities.
One of the strongest advantages of TMS is that it is not a systemic medication. It does not circulate through the digestive tract, liver, or bloodstream in the same way oral antidepressants do. For patients who have struggled with medication side effects such as weight gain, sexual side effects, sedation, or emotional blunting, that can be a meaningful benefit.
How Spravato works for treatment-resistant depression
Spravato is administered as a nasal spray in a certified medical office under supervision. After each treatment, patients stay for observation because the medication can cause perceptual changes, dizziness, sleepiness, nausea, or a feeling of being disconnected. You cannot drive after treatment, so transportation planning is part of the process.
The appeal of Spravato is that some patients notice improvement faster than they did with standard antidepressants. That does not mean immediate or guaranteed relief, but its mechanism can be especially valuable for adults who have been stuck in severe, persistent depression despite multiple medication trials.
Spravato is usually used along with an oral antidepressant rather than as a stand-alone treatment. The schedule is often more frequent at the beginning and then tapers based on response. Because it is a medication with specific monitoring requirements, eligibility depends on a detailed psychiatric and medical review.
Who may be a better fit for TMS
TMS is often a strong option for adults with major depression who have not responded well to antidepressants or who cannot tolerate medication side effects. It may also appeal to people who want a non-drug treatment with no recovery period after sessions.
Patients who value structure often do well with TMS. You come in, complete the session, and continue your day. There is no dissociative experience to recover from, and cognitive side effects are not expected. For many people, that predictability lowers the stress around starting treatment.
TMS can also be attractive when long-term medication burden is a concern. If someone has already tried several medications without meaningful relief, adding another medication may feel discouraging. A device-based approach can offer a different path without repeating the same cycle.
That said, TMS requires consistency. The schedule is frequent, especially early on, and results usually build over time rather than after one or two sessions. Patients looking for the fastest possible shift in symptoms may find that important when comparing options.
Who may be a better fit for Spravato
Spravato may be appropriate for adults with treatment-resistant depression who need an advanced option after multiple unsuccessful antidepressant trials. It can be especially relevant when symptoms are severe and a psychiatrist believes a glutamate-based treatment could offer breakthrough relief.
Some patients choose Spravato because they want a treatment that may begin helping sooner than a full TMS course. Others prefer it because they are more comfortable with a medication-based approach than with daily device treatments over several weeks.
Still, Spravato is not the easier choice just because it is a nasal spray. Each session requires in-office monitoring, and side effects on treatment days can limit the rest of your schedule. If you work full time, care for children, or have limited transportation, those practical issues matter.
Side effects and safety considerations
TMS is generally well tolerated. The most common side effects are scalp discomfort or headache during or after treatment, especially early in the course. These symptoms are often mild and tend to lessen as treatment continues. Serious risks are uncommon, but seizure risk is reviewed carefully before starting.
Spravato has a different safety profile. Dissociation, dizziness, increased blood pressure, nausea, and sedation are among the side effects clinicians monitor for during each visit. Because of these effects, treatment must be given in a controlled medical setting with observation afterward.
Neither option should be chosen based on marketing language alone. Safety depends on screening, diagnosis, medication review, substance use history, and a treatment plan guided by an experienced psychiatric team. That is one reason a board-certified psychiatrist evaluation matters so much before deciding.
What response can look like
Some patients have a clear response to one treatment and not the other. That is frustrating, but it is also common in psychiatry. Depression is not one-size-fits-all, and treatment-resistant depression especially requires personalization.
With TMS, improvement may show up gradually. Sleep may improve first. Then motivation, focus, and emotional resilience may begin to return. For Spravato, some patients notice early changes in mood or intensity of depressive symptoms, while others need more time and close follow-up before benefits become clear.
The best outcome usually comes from looking beyond the treatment itself. Medication management, psychotherapy, sleep, substance use, medical conditions, and family stress all affect recovery. Advanced treatment works best when it is part of a broader psychiatric care plan rather than a stand-alone fix.
TMS vs Spravato depression treatment: questions worth asking
If you are deciding between these options, start with practical and clinical questions. Have you failed multiple antidepressants because they did not work, because side effects were intolerable, or both? Do you need to drive yourself home after treatment? Are your symptoms urgent, severe, and unrelenting, or are you looking for a non-invasive alternative with minimal disruption to your day?
It also helps to ask how your anxiety, trauma history, bipolar symptoms, substance use, and other medical conditions may affect the decision. A treatment that sounds promising online may not be the safest or most effective fit in real life.
For patients in Saginaw and surrounding communities, getting evaluated by a psychiatric team that offers both options can be especially helpful. When one clinic can assess TMS and Spravato side by side, the recommendation is more likely to be based on clinical fit instead of a one-treatment-only model.
Choosing the right next step
TMS and Spravato both represent meaningful progress in depression care. Neither is a shortcut, and neither is right for everyone. The better option is the one that matches your diagnosis, prior treatment history, side effect tolerance, schedule, and safety needs.
If you have been living with depression that keeps returning or never fully lifts, this decision deserves more than guesswork. A thoughtful psychiatric evaluation can clarify whether a non-invasive, FDA-cleared treatment like TMS or a monitored medication approach like Spravato offers the stronger path forward. Sometimes hope starts with hearing that there is still another evidence-based option to try.